3[1]Mountain CF. A new international staging system for lung cancer. Chest,1986,89(4 Suppl)∶225S-233S.
4[3]Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest,1997,111(6)∶1710-1717.
5[4]Wu YL, Huang ZF, Wang SY, et al. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer,2002,36(1)∶1-6.
6[6]Izbicki JR, Pantel K, Hosch SB. Micrometastasis in solid epithelial tumors: impact on surgical oncology. Surgery,2002,131(1)∶1-5.
7[8]Sondak VK. How does interferon work? Does it even matter? Cancer,2002,95(5)∶947-949.
8[9]Jassem J. Biological treatment of NSCLC. The need for conclusive studies. Chest,1996,109(5 Suppl)∶119S-124S.
9[10]Masotti A, Morandini G, Ortolani R, et al. Phase-Ⅱ randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer,1998,20(3)∶191-202.
10[13]Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer,2002,95(5)∶1101-1112.
